MedTrace Logo

Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions

NCT03410836 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-10-18

No results posted yet for this study

Summary

This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.

Conditions

  • Intravenous Lidocaine and Immunity

Interventions

DRUG

intravenous lidocaine (IVL)

lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).

OTHER

Placebo

Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).

Sponsors & Collaborators

  • Foundation of Anesthesia and Resuscitation of Quebec

    collaborator UNKNOWN

  • Ciusss de L'Est de l'Île de Montréal

    lead OTHER

Principal Investigators

  • Philippe Richebé, MD, PhD · CIUSSS Est de l'ile de Montreal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03410836 on ClinicalTrials.gov